ArticleJournal of clinical pathology1991
c-erbB-2 expression in different histological types of invasive breast carcinoma.
Article in Journal of clinical pathology, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 82 citations in OpenAlex.
- Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS.Breast cancer research and treatment · 2025Article
- Rare Breast Cancer Histotypes-A Retrospective Study and Literature Review.Journal of clinical medicine · 2024Article
- Antiproliferative and proapoptotic activities of Sea Cucumber H. Leucospilota extract on breast carcinoma cell line (SK-BR-3).Molecular biology reports · 2022Article
- Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods.Insights into imaging · 2014Article
- Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society.Journal of cancer research and clinical oncology · 2014Review
- ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.Breast cancer research and treatment · 1995Article
- Protein kinases in human breast cancer.Breast cancer research and treatment · 1995Review
- Epidermal growth factor receptor immunohistochemistry in different histological types of infiltrating breast carcinoma.Journal of clinical pathology · 1993Article
- Prognostic significance of c-erbB-2 expression in node negative breast cancer.British journal of cancer · 1993Article
- Article
- c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.Journal of clinical pathology · 1992Article
- HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer.Anticancer researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sections of 149 breast carcinomas were examined for the over-expression of c-erbB-2 oncoprotein using the avidin-biotin immunoperoxidase technique and two different specific antibodies. These included the polyclonal antibody 21N and the monoclonal antibody 4D5. The tumours were divided into two main groups. The first included 75 cases of invasive ductal and classic invasive lobular carcinomas. The second group consisted of 74 cases with histological types known to have a good prognosis, including mucinous, alveolar variant of invasive lobular, medullary, tubular, cribriform and papillary carcinomas. Fifteen (20%) tumours of the first group were positive with the two antibodies. Fourteen of these were of the ductal type and one was a mixed invasive ductal and lobular carcinoma. Ten of the pure ductal cases had areas of comedo carcinoma. The intraductal elements in a further tumour were positively stained with 21N antibody only. None of the second group of tumours, which included histological types known to have good prognosis, stained with 4D5, although one mucinous carcinoma was positively stained with 21N. These findings suggest that in invasive breast carcinoma immunostaining for c-erbB-2 is mainly seen in a subgroup of ductal tumours, and that almost all other histological types, especially those associated with good prognosis, lack this expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.